Acrux and its partner Padagis announced the launch of an AB-rated generic version of Emla® Cream in the United States. Emla® (prilocaine 2.5% and lidocaine 2.5%) Cream is indicated as a topical anaesthetic for use on: normal intact skin for local analgesia; and genital mucous membranes for superficial minor surgery and as pre-treatment for infiltration anaesthesia.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.062 AUD | +1.64% | -1.59% | +40.91% |
04-03 | Acrux, TruPharma Launch Dapsone 5% Gel in US | MT |
02-29 | Transcript : Acrux Limited, H1 2024 Earnings Call, Feb 29, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+40.91% | 11.85M | |
+21.65% | 43.92B | |
+24.56% | 23.09B | |
+19.18% | 15.35B | |
+14.01% | 13.61B | |
+46.54% | 12.02B | |
-10.14% | 7B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+13.07% | 5.6B |
- Stock Market
- Equities
- ACR Stock
- News Acrux Limited
- Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States